Spyre Therapeutics doses first subjects in Phase I IBD treatment trial [Yahoo! Finance]
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-a4ß7 Antibody, for the Treatment of Inflammatory Bowel Disease [Yahoo! Finance]
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-a4ß7 Antibody, for the Treatment of Inflammatory Bowel Disease
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference [Yahoo! Finance]